REGENXBIO Inc. (Nasdaq: RGNX) today announced a program update from its ongoing clinical investigation of RGX-314 for the treatment of wet AMD, a leading cause of vision loss globally.Read more
Showcase your company’s growth by promoting your new hires and recent promotions to the BioBuzz audience.
Most Recent Press Release
Submit your Press Release
Start sending releases with one of the largest and most trusted Biosciences content distribution network.Submit Today